Core Insights - Amgen presented new data on IMDELLTRA (tarlatamab-dlle), a bispecific T-cell engager targeting DLL3, at the 2024 World Conference on Lung Cancer, highlighting its potential in treating extensive-stage small cell lung cancer (ES-SCLC) [1][2][3] DeLLphi-303 Study Results - The Phase 1b DeLLphi-303 study showed that IMDELLTRA combined with PD-L1 inhibitors as first-line maintenance therapy in ES-SCLC had a manageable safety profile and positive survival outcomes [3][4] - IMDELLTRA plus durvalumab achieved a disease control rate (DCR) of 62.5% and a 9-month overall survival (OS) of 91.8% [3][4] - IMDELLTRA plus atezolizumab also demonstrated a DCR of 62.5% with a median duration of disease control of 7.2 months and a 9-month OS of 86.7% [3][4] DeLLphi-301 Study Results - Long-term follow-up data from the Phase 2 DeLLphi-301 study indicated an objective response rate (ORR) of 40% among 100 patients treated with IMDELLTRA [5][6] - The median OS for this group was reported at 15.2 months, with stable disease observed in 30% of patients [5][6] IMDELLTRA Overview - IMDELLTRA received accelerated approval from the FDA for patients with ES-SCLC who progressed after platinum-based chemotherapy [3][11] - The drug targets DLL3, which is expressed in approximately 85-96% of SCLC patients, making it a promising therapeutic target [10][11] Future Studies - Ongoing trials, including the Phase 3 DeLLphi-305 trial, will further evaluate the efficacy of IMDELLTRA in combination with PD-L1 inhibitors [3][4][6] - The DeLLphi-303 study is designed to assess the safety and efficacy of IMDELLTRA in combination with standard-of-care therapies in first-line ES-SCLC [6][8]

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, widely recognized as a standard of care treatment option for severe emphysema [2] Upcoming Event - Pulmonx will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, at 1:30 PM PT / 4:30 PM ET [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.88%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.36, delivering a surprise of 16.28%. Over the last four quarters, the company has sur ...

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basis Delivered $13.9 million in U.S. revenue i ...

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard of care treatment option for severe emphysema [2] Product and Market - The Zephyr Valve is designated as a "breakthrough device" by the FDA, highlighting its innovative nature and potential impact on patient care [2] - The Zephyr Valve is included in global treatment guidelines, indicating its widespread acceptance and adoption in the medical community [2] Investor Relations - Pulmonx Corporation will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 5:00 AM PT / 8:00 AM ET [4] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]

Core Insights - Pulmonx's existing strategy is gaining traction, with Q1 revenues of $18.9 million reflecting a 30% year-over-year growth [3][15] - The company is not expected to make significant strategic changes in the near term, focusing instead on refining its current approach [6][30] - Despite positive revenue growth, Pulmonx's operating expenses significantly exceed revenues, leading to a projected breakeven point not expected until 2026 at the earliest [16][42] Financial Performance - Pulmonx reported Q1 revenues of $18.9 million, a 30% increase compared to the previous year [3][15] - Total operating expenses for Q1 were $28.6 million, resulting in a net loss of $13.7 million, an improvement from a loss of $15.9 million in the same quarter last year [7][16] - The company has a market capitalization of $307 million and an enterprise value of $228 million, with significant stock-based compensation impacting financials [12][20] Strategic Focus - The company aims to enhance physician awareness and best practices while continuing to attract large users of its Zephyr Valve [2][25] - There is a focus on maintaining existing strategies rather than pursuing mergers and acquisitions, despite the potential for a large total addressable market [30][40] - The CEO has indicated that while the strategy may need fine-tuning, no major shifts are anticipated in the immediate future [6][28] Future Outlook - Analysts forecast conservative revenue growth, with expectations of only high teens growth rates for upcoming quarters [21][36] - The company is positioned for a potential 'beat-and-raise' quarter due to strong sales momentum against conservative estimates [36][47] - Concerns remain regarding the company's ability to sustain operations until reaching breakeven, with estimates suggesting a need for approximately $160 million in operating losses before achieving this milestone [45][46]

Core Insights - Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, will release its financial results for Q2 2024 on July 31, 2024, after market close [1] - A conference call to discuss these results will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Company Overview - Pulmonx Corporation specializes in treatments for chronic obstructive pulmonary disease (COPD) and offers products such as the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized as a standard treatment option for severe emphysema [3] - The company's products aim to improve breathing, activity levels, and quality of life for patients suffering from severe emphysema/COPD [3]

Core Viewpoint - Pulmonx Corporation (LUNG) shares have increased by 17.1% recently, with analysts suggesting a potential upside of 80.3% based on a mean price target of $15.83 [1][10]. Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $1.72, indicating variability among analysts [2]. - The lowest price target of $14 suggests a 59.5% increase, while the highest target of $18 indicates a potential surge of 105% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [8]. Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about LUNG's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [10]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 8.7%, with two estimates moving higher and no negative revisions [11]. - LUNG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12].

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult p ...